Market Overview

UPDATE: Cantor Fitzgerald Initiates Coverage on Myriad Genetics on Position in Molecular Diagnostic Franchises

Related MYGN
A Closer Look At 5 Heavily Shorted Stocks
Study Shows Prolaris Could Save Healthcare System $6B Over 10 Yrs.

In a report published on Friday, analysts at Cantor Fitzgerald initiated coverage on Myriad Genetics (NASDAQ: MYGN) with a Buy rating and $40 PT.

In the report, lead analyst Sung Ji Nam commented that, "We are initiating coverage of MYGN with a BUY rating and $40 PT. With its current flagship product BRACAnalysis, MYGN has built one of the most successful, high-value molecular diagnostic franchises (~$500mm business), and we believe the company is well-positioned to execute industry-leading growth (top and bottom lines) over the next several years, driven by its competitive product portfolio and pipeline, as well as unmatched capabilities in diagnostic research, market development and commercialization capabilities."

Myriad Genetics closed on Thursday at $31.06

Latest Ratings for MYGN

DateFirmActionFromTo
Nov 2014Morgan StanleyInitiates Coverage onUnderperform
Aug 2014Credit SuisseMaintainsNeutral
Jun 2014MacquarieMaintainsNeutral

View More Analyst Ratings for MYGN
View the Latest Analyst Ratings

Posted-In: Cantor Fitzgerald Sung Ji NamAnalyst Color Initiation Analyst Ratings

 

Related Articles (MYGN)

Around the Web, We're Loving...

Get Benzinga's Newsletters